BRZ-101
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About BreezeBio
BreezeBio, founded in 2021 and based in San Diego, is a private biotech advancing a novel programmable nanoparticle platform, NanoGalaxy®, for the targeted delivery of genetic medicines. The company is initially focused on restoring immune balance in autoimmune diseases, with a lead program (BRZ-101) in Type 1 Diabetes and a broader pipeline in autoimmunity and oncology. BreezeBio has secured significant venture financing and established key partnerships with Genentech and Sarepta Therapeutics, positioning it as a promising player in the next generation of genetic medicine delivery.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |